Healthcare, Pharma & Life Sciences

Toronto – November 10, 2026 -- Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) will put three senior executives in front of investors at the Stifel 2026 Healthcare Conference in New York City, with President Richard Fabian presenting on Thursday, November 12, 2026, at 8:40 a.m. Eastern Time.

Profound will broadcast Fabian's November 12 session live and archive it online

The commercial-stage interventional MRI (iMRI) company will make the webcast available on its website. Chief Executive Officer and Chairman Arun Menawat and Chief Financial Officer Matthew Sobczyk will join Fabian for one-on-one investor meetings during the conference.

Investors seeking a one-on-one slot must go through their Stifel representative.

VANCOUVER – November 10, 2026 -- WAT Medical Enterprise Ltd. is renewing its US$1 donation to The American Legion for every HeadaTerm 2 device sold, marking the eighth consecutive year of the program and widening its veteran-focused support to device donations, purchase discounts and clinical research.

WAT Medical ties veteran giving directly to HeadaTerm 2 unit sales

The per-unit donation to The American Legion links the company's charitable spending to sales volume of HeadaTerm 2, its wearable device. The product is FDA-cleared for the prevention of episodic migraine in adults and is marketed as a portable, drug-free option.

Jupiter – November 10, 2026 -- Myosin Therapeutics plans to move its MT-125 glioblastoma trial into Phase 2 in early 2027, with the Phase 1 dose-escalation stage running ahead of schedule, the company said ahead of the Society for Neuro-Oncology (SNO) meeting in Philadelphia.

CEO and CMO to meet investigators and prospective partners at SNO

CEO Courtney Miller and CMO Karen Smith will attend the 31st SNO Annual Meeting, running November 12-15, 2026. They will meet current clinical investigators and potential development partners to discuss the Phase 1/2 STAR-GBM trial and preparations for the Phase 2 transition.

Miller said the company's focus is on "solidifying the clinical and strategic relationships" needed for the next development stage.

THOUSAND OAKS, Calif. – November 10, 2026 -- Amgen reported that an independent health economic analysis of its PCSK9 inhibitor Repatha (evolocumab) found the drug cost-effective at approximately 36% below the ACC/AHA benchmark in high-risk patients with no prior heart attack or stroke. The company presented the data at the American Heart Association (AHA) Scientific Sessions 2026.

Duke-led analysis uses patient-level VESALIUS-CV data

The Duke Clinical Research Institute led the study with the TIMI Study Group at Mass General Brigham and Harvard. It is the first independent health economic analysis built on individual-participant data from the Phase 3 VESALIUS-CV trial, and it compared treatment costs with projected health benefits. A separate analysis found that adding Repatha to standard therapy was highly cost-effective versus standard therapy alone in adults with atherosclerotic cardiovascular disease (ASCVD).

Bloomington, Indiana – November 10, 2026 -- Simtra BioPharma Solutions has opened Building H, a more than $250 million expansion of its Bloomington manufacturing campus that adds prefilled syringe, vial and lyophilization capabilities for sterile injectable products.

153,000-square-foot facility adds three production capabilities

The contract development and manufacturing organization (CDMO), which focuses exclusively on sterile injectables, said Building H widens the range of injectable products it can support. Indiana Governor Mike Braun and Bloomington Mayor Kerry Thomson spoke at the ribbon-cutting. The expansion is expected to create hundreds of jobs in Bloomington.

Wayne, N.J. – November 10, 2026 -- Forty-five technologists and technologist aides at ImageCare in Sussex County, N.J., have gone on strike after nearly two years without a first union contract, Teamsters Local 125 said.

Workers Cite Wages and Health Care Costs as Core Demands

The workers voted to join the Teamsters almost two years ago. They are seeking better wages and affordable health care in a first agreement.

Local 125 President Paxton Ryan accused the company of bad-faith bargaining and of refusing to offer a contract that recognizes members' worth. He said the union will stand firm until ImageCare addresses workers' concerns.

Canton, Ohio – November 10, 2026 -- Liberty HealthShare awarded $25,000 in grants to five Stark County hunger relief organizations, bringing its total giving to $50,000 over two annual "Day of Sharing" events.

Five organizations each receive $5,000 through the Sharing Hearts Fund

The nonprofit healthcare sharing ministry presented the grants through its charitable arm, the Sharing Hearts Fund. Recipients are Alliance Community Pantry, City Serve Food Pantry & Café, Compassion Delivered, Feed Kids First and Lake Township FISH. The money is intended to help the organizations supply food to thousands of individuals and families facing food insecurity across the county.

CEO Dorsey Morrow said the ministry was proud to back the groups for a second consecutive year and "continue this important work."

SCHAUMBURG, Ill. – November 10, 2026 -- Hospitals where each nurse cared for four or fewer patients recorded average emergency department boarding times about 20 minutes shorter than hospitals where one nurse handled five or more patients, according to a study in the November issue of the Journal of Emergency Nursing (JEN).

Study of 335 hospitals in three states links staffing ratios to boarding times

Researchers reviewed nurse staffing data and ED boarding times from 335 hospitals in Florida, New Jersey and Pennsylvania. JEN describes the work as a first-of-its-kind study. The Emergency Nurses Association (ENA) publishes the journal.

Oklahoma City – November 10, 2026 -- Hospice agencies can deliver blood and platelet transfusions at home to patients with blood cancers at a cost of $571 per patient per week, according to a University of Oklahoma pilot study of 20 people. The researchers hope the data will support a federal reimbursement model for the service.

Pilot Study Reports No Hospitalizations or Transfusion Reactions

Published in eClinicalMedicine, a journal in The Lancet family, the study covered patients who had stopped pursuing treatment aimed at controlling their cancer. Hospice-administered transfusions kept hemoglobin and platelet levels within a range consistent with clinical transfusion guidelines. No patients were admitted to the hospital or intensive care unit, and no transfusion reactions were reported.

Toronto -- Syneos Health experts will lead a free webinar on December 1, 2026, at 11am EST (5pm CET) on how neuroscience sponsors are changing patient identification, endpoint selection and treatment-response assessment across CNS disorders. Xtalks is hosting the session, titled "Neuroscience Development: Are We Measuring What Matters?"

Disease heterogeneity and response variability are pressuring traditional trial design

Alzheimer's disease, Parkinson's disease and psychiatry trials face disease heterogeneity, limited trial accessibility and variable treatment response. These factors are forcing sponsors to reassess how they identify patients, measure treatment effects and make development decisions. Panelists will examine why traditional measures of treatment response are being re-examined and how sponsors are evaluating endpoints that better capture clinically meaningful change.